OTLK OUTLOOK THERAPEUTICS INC
Company Analysis
Latest News
Outlook Therapeutics Faces 17.3M Share Sale, Signaling Potential Dilution
Outlook Therapeutics disclosed a new share offering in a July 17, 2026, regulatory filing. Selling stockholders plan to offer up to 17.26 million common...
Outlook Therapeutics Hands Its Board a Blank Check on Shares — But Can an FDA Decision 12 Days Away Save the Stock?
Shares of Outlook Therapeutics sank 8.9% to $1.35 after a July 16 special shareholder meeting gave management sweeping new authority over the company's share...
🔴 Outlook Therapeutics is trading 8.9% down today after shareholders approved a share increase and potential reverse stock split
Outlook Therapeutics is trading 8.9% down at $1.35 following a special shareholder meeting that approved an increase in authorized common shares and a...
Outlook Therapeutics Stockholders Approve Increase in Authorized Shares and Reverse Stock Split
Outlook Therapeutics announced that at a Special Meeting on July 16, 2026, its stockholders approved several key proposals. These include a significant...
🔴 Outlook Therapeutics is trading 6.1% down today amid broader biotech sector weakness
Outlook Therapeutics is trading at $1.47 (-6.09%) following a sharp pullback from the previous session’s close, likely pressured by broader weakness across the...
🟢 Outlook Therapeutics is trading 14.8% up
Outlook Therapeutics is trading at $1.78, up 14.8% from a comparison close of $1.55 during regular trading. This is a price-action follow-up, so a separate...
Outlook Therapeutics Rallies Toward FDA Decision Day — But Can a 17-Person Company Turn One Drug Into a Real Business?
Shares of Outlook Therapeutics surged 12.3% to $1.74 on July 14, defying broader biotech weakness as traders pile into the stock ahead of a make-or-break FDA...
🟢 Outlook Therapeutics is trading 8.5% up today on positioning ahead of FDA decision for Lytenava
Outlook Therapeutics is trading 8.5% up at $1.74 as traders continue to position ahead of the upcoming FDA decision on its eye drug Lytenava. • The upward...
🔴 Outlook Therapeutics is trading 5.65% down today on profit-taking after recent PDUFA-driven rally
Outlook Therapeutics is trading at $1.58 (5.65% down) as the stock experiences a pullback following a sharp multi-day run-up. • The recent rally was fueled...
🟢 Outlook Therapeutics is trading 10.1% up
Outlook Therapeutics is trading at $1.86, up 10.1% from a comparison close of $1.69 during regular trading. This is a price-action follow-up, so a separate...
🟢 Outlook Therapeutics is trading 6.2% up today on FDA acceptance of BLA for ONS-5010
Outlook Therapeutics is trading 6.2% up at $1.81 as investors position ahead of a key regulatory milestone for its lead retinal therapy. • The FDA has...
🟢 OTLK makes sharp 13.7% jump
OTLK is trading at $1.66, up 13.7% versus the comparison close of $1.46 during regular trading. This is a price-movement alert; no separate company-specific...
🟢 OTLK is trading 6.2% up today on positioning ahead of July FDA decision
OTLK is trading 6.2% up today at $1.55 on follow-through positioning ahead of a July FDA action date for its wet-AMD drug, Lytenava. • The move extends a mild...
🟢 OTLK is trading 5.7% up today on continued momentum from FDA appeal victory and BLA resubmission
OTLK is trading 5.7% up at $1.53 following a recent FDA appeal victory and the June 1 BLA resubmission for ONS-5010 (Lytenava). • The FDA confirmed that...
🟢 OTLK is trading 7.8% up today with no clear company-specific catalyst
OTLK is trading 7.8% up now at $1.58 after two weak sessions and recent volatility around the $1.50–$1.70 range. No fresh company-specific news, earnings, FDA...
🔴 OTLK down 5% today following recent rally fueled by FDA BLA acceptance and Nasdaq compliance
• OTLK is trading 5% down at $1.60 today, likely due to profit-taking after its recent rally. • The rally was driven by the FDA's acceptance of the resubmitted...
Outlook Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Rule
Outlook Therapeutics, Inc. has received notification from Nasdaq confirming that it has regained compliance with the minimum bid price requirement for...
🟢 OTLK makes sharp 10.9% jump
OTLK is trading at $1.78, up 10.9% versus the comparison close of $1.61 during regular trading. This is a price-movement alert; no separate company-specific...
🟢 OTLK is trading 7.1% up today as it rebounds from profit-taking following FDA BLA acceptance
OTLK is trading 7.1% up at $1.73, rebounding after yesterday’s profit-taking dip that followed a sharp rally driven by regulatory progress. • The primary...
🔴 OTLK is trading 5.1% down today as traders take profits following its recent FDA-driven rally
OTLK is trading at $1.59 (down 5.1%) as the stock experiences a pullback following a significant rally sparked by positive regulatory news. • The recent surge...